PDE5-IN-1 

PDE5-IN-1 (compound 2) is a PDE5 inhibitor with an IC₅₀ of 5.6 nM and oral bioavailability. PDE5-IN-1 forms hydrogen bond interactions with the Q817 residue in the catalytic domain of PDE5, and aromatic π-π stacking interactions with the F820 residue. PDE5-IN-1 exerts anti-cardiac hypertrophy and vasodilatory effects, reduces mean pulmonary arterial pressure and right ventricular hypertrophy index. PDE5-IN-1 can be used in the research of pulmonary arterial hypertension^[1].

PDE5-IN-1 (compound 2) (multiple concentrations; 15 min) potently inhibits the PDE5A catalytic domain with an IC₅₀ of 5.6 nM^[1].
PDE5-IN-1 (multiple concentrations; 15 min) shows remarkable selectivity for PDE5A over other PDE families, with selectivity indices ranging from 10 (vs PDE6A) to >1700 (vs PDE1B, PDE3A, PDE7A1, PDE9A2)^[1].
PDE5-IN-1 (multiple concentrations) has weak inhibitory effects on major human hepatic CYP isoenzymes, with only moderate inhibition of CYP1A2 (IC₅₀ = 7.6 μM) and no significant inhibition of six other key isoenzymes^[1].
PDE5-IN-1 (multiple concentrations) shows weak inhibition of the hERG potassium channel, with an IC₅₀ >10 μM^[1].
PDE5-IN-1 (0.5 μM; incubated to determine T_1/2) is stable in both rat and human liver microsomes, with significantly longer half-lives than the positive control midazolam^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PDE5-IN-1 (compound 2) (5.0 mg/kg; p.o.; daily; 3 weeks) produces a statistically significant reduction in mPAP and RVHI in MCT-induced PAH rats, with superior efficacy to sildenafil citrate at 10.0 mg/kg^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

402.42

C₂₂H₁₄N₂O₄S

2109805-65-2

O=C1C=2C=CC=CC2OC=3C1=C(NC3CC4=CC=C5OCOC5=C4)C6=NC=CS6

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wu D,et al. Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension. J Med Chem. 2017 Aug 10;60(15):6622-6637.  [Content Brief]